QIBA SPECT Biomarker Committee (BC)  
Friday, April 21, 2017, 9 AM (CT)  
Call Summary

In attendance:  
- Yuni Dewaraja, PhD (Co-Chair)  
- John Dickson, PhD  
- Robert Miyaoka, PhD  
- Joe Koudelik  
- P. David Mozley, MD (Co-Chair)  
- Abhinav Kumar Jha, PhD  
- Eric Perlman, MD  
- Julie Lisiecki  
- John Seibyl, MD (Co-Chair)  
- Paul Kinahan, PhD  
- Brian Zimmerman, PhD  
- Anna Celler, PhD

Moderator: Dr. Mozley

I-123 Ioflupane Profile

- Recent Process Committee recommendations for Public Comment responses were reviewed
- Two additional columns have been suggested
  - A Proposal column – which contains only the actual text changes being proposed
  - An Issues column – which contains additional information, e.g., what the problem is, preferences to address issues, rationale for changes
- This Process Committee suggestion seeks to make it easier for BCs to respond to proposed changes as follows:
  - Accept both the issue and the proposed solution
  - Agree with the issue but decide on a variant or completely different solution
  - Reject the issue
- Dr. Perlman suggested use of highlighting and different colored fonts to aid with categorizing responses to Profile comments, e.g., help identify which issues had been addressed vs. which were still outstanding, and subject matter expert needed
  - Cyan was used to indicate medical physics issues
  - Yellow was tagged for physician input
  - Green was for the entirety of the BC to review
- Dr. Mozley recognized Mr. Cella and GE Healthcare for their helpful contribution of I-123 DaT data
  - BC and Task Force calls plan to address the Ioflupane I-123 Profile comments to advance the Profile and work in parallel to accelerate work on the Profile for Technetium-99m in oncology and immunology
  - The group is aiming to have the Ioflupane I-123 Profile completed by July 1st
  - Public comments for the I-123 Profile are being addressed on Tuesday TF calls

Some committee reorganization

- A new Profile focus on Technetium (Tc $^{99m}$) and test-retest studies will begin to work in parallel on the TF calls, starting in the Q3 2017
- The original four I-123 TFs will soon be decommissioned and replaced by two new Profile writing teams for I-123 and Tc$^{99m}$
- To facilitate this, shifts in leadership have been suggested as follows:
  - Drs. Dickson and Seibyl will continue to lead the Ioflupane Profile writing effort
  - Drs. Dewaraja and Mozley will initiate the Technetium-$^{99m}$ Profile effort
- Current participants interested in participating on one or both of these committees are asked to make their preference known by responding to RSNA Staff (jlisiecki@rsna.org) or Dr. Mozley (mozley@gmail.com)
- Technical scribes may be needed for these calls. If interested, please respond to Dr. Mozley (mozley@gmail.com)

Leadership transitions forecast

- Opportunities for new leadership will be available in late 2017 or early 2018, and all are asked to consider these leadership roles:
  - Co-chair of the SPECT BC
Co-chair of the QIBA Nuclear Medicine Coordinating Committee (WebEx meetings are quarterly) along with WebEx meetings that may arise with nuclear medicine leadership.

New members
- In addition, all are asked to recruit new members regularly; new names can be sent to qiba@rsna.org
- Volunteers willing to moderate BC or TF calls would be appreciated
  - Please email the SPECT BC co-chairs if interested: yuni@umich.edu; mozley@gmail.com; jseibyl@mnimaging.com
- Previous meeting agendas, Profile versions, and work products are available in the group’s Dropbox folder
- Opportunities to meet and recruit new members may present themselves at the following meetings:
  - June, Colorado: SNMMI informal meeting with QIBA-Japan
  - October, Vienna: EANM annual meeting
  - December, Chicago: RSNA annual meeting

Groundwork related to the I-123 Profile
- Some comments cannot be resolved until Round-6 groundwork has been completed
  - Comments related to groundwork will be deferred
  - Version 1.0 will be based on the outcome of SPECT groundwork projects
- Supplemental NIBIB awards associated with larger (e.g., R01s) were discussed as an option for all PIs to consider

The next call will be the second Tuesday in May for the next task force meeting.

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries. QIBA wiki